Today before the opening
bell, Advaxis, a biotechnology company developing the next generation of cancer
immunotherapies, announced it had signed an agreement with SynCo Bio Partners
to manufacture Advaxis’ leading drug candidate, ADXS-HPV. Under the terms of the
agreement, SynCo Bio Partners will be assisting Advaxis in development of
scale-up and commercial manufacturing processes for ADXS-HPV bulk drug
substance and drug product.
As Advaxis’ lead
immunotherapy for the treatment of HPV-associated cancers, ADXS-HPV showed
strong increased survival and objective tumor responses in a Phase 2 trial
featuring 110 patients with recurring cervical cancer. In this year, Advaxis
plans to begin registrational trials for patient treatment of cervical cancer
with ADXS-HPV.
“SynCo’s ability to
manufacture both drug substance and drug product for ADXS-HPV will offer us
increased flexibility as we expand our manufacturing process in preparation for
commercial-scale production,” commented Daniel J. O’Connor, Chief Executive Officer
of Advaxis. “To have the support of a world-class manufacturer, such as SynCo,
is pivotal to our ability to make ADXS-HPV available to patients on a global
scale, upon approval.”
Pierre Warffemius, Chief
Executive Officer of SynCo Bio Partners, commented, “SynCo is very pleased to
enter into a long-term manufacturing collaboration and looks forward to working
with Advaxis to support global licensure of ADXS-HPV. Our leading position for
supply of live microbial biopharmaceuticals, through providing high quality
manufacturing services, will bring this therapeutic vaccine safely to patients
for the treatment of HPV-associated cancers.”
For more information, visit:
www.advaxis.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
